Satellite Symposia Programme

    13:45 - 14:45 
    Childhood cancer survivors: endocrine late effects and management of growth hormone deficiency
    Novo Nordisk
    Hall A
    Michel Polak (France)
    13:45
    Hall A
    Session starts at 13:45
    SAT1.1
    Opening remarks
    Michel Polak (France)

    13:50
    Hall A
    Session starts at 13:45
    SAT1.2
    Childhood cancer treatments and associated endocrine late effects

    14:10
    Hall A
    Session starts at 13:45
    SAT1.3
    How best to treat a childhood cancer survivor with growth hormone deficiency
    Lars Sävendahl (Sweden)

    14:30
    Hall A
    Session starts at 13:45
    SAT1.4
    Panel discussion
    All

    13:45 - 14:45 
    Clinical Study of Pegylated Long-acting Growth Hormone in Children with Growth Hormone Deficiency
    GeneScience Pharmaceuticals Co., Ltd. (GenSci)
    Hall B
    Bradley S Miller (USA)
    13:45
    Hall B
    Session starts at 13:45
    SAT2.1
    Clinical Study of Pegylated Long-acting Growth Hormone in Children with Growth Hormone Deficiency
    Xiaoping Luo (China)

    18:30 - 20:00 
    Management of paediatric short stature patients - looking to the future
    Pfizer
    Hall A
    Marie-José Walenkamp (Netherlands)
    18:30
    Hall A
    Session starts at 18:30
    SAT3.1
    Opening Remarks
    Marie-José Walenkamp (Netherlands)

    18:35
    Hall A
    Session starts at 18:30
    SATd3
    DEBATE: Patients with paediatric short stature should undergo genetic screening

    18:35
    Hall A
    Session starts at 18:30
    SATd3.1
    DEBATE: Pro - "Molecular diagnosis is beneficial for short stature patients"

    18:50
    Hall A
    Session starts at 18:30
    SATd3.1
    DEBATE: Against - "Molecular diagnosis is of no benefit for the vast majority of short stature patients"
    Lars Sävendahl (Sweden)

    19:05
    Hall A
    Session starts at 18:30
    SAT3.4
    Q&A and voting
    Marie-José Walenkamp (Netherlands)

    19:15
    Hall A
    Session starts at 18:30
    SAT3.5
    Short stature diagnosis and management: Key insights from the 2019 GRS Consensus Group

    19:35
    Hall A
    Session starts at 18:30
    SAT3.6
    Emerging diagnostic tools and therapies for short stature

    19:55
    Hall A
    Session starts at 18:30
    SAT3.7
    Q&A and meeting close
    All

    18:30 - 20:00 
    Starting puberty at the right time: Optimising treatment to deliver long-term outcomes for patients with CPP
    Ipsen
    Hall C
    Jean-Claude Carel (France)
    18:30
    Hall C
    Session starts at 18:30
    SAT4.1
    Chairperson’s welcome and introduction

    18:35
    Hall C
    Session starts at 18:30
    SAT4.2
    Improving CPP management: The insights and challenges of developing a national registry
    Catarina Limbert (Portugal)

    18:55
    Hall C
    Session starts at 18:30
    SAT4.3
    Flexible treatment options: what a 6 month formulation means for patients with CPP
    Karen Klein (USA)

    19:15
    Hall C
    Session starts at 18:30
    SAT4.4
    Long term outcomes with GnRHa: Treating patients with CPP
    Liat de Vries (Israel)

    19:35
    Hall C
    Session starts at 18:30
    SAT4.5
    Moving Forward Together

    18:30 - 20:00 
    Human and ehealth partnership for effective management of growth disorders
    Merck
    Hall B
    Martin Savage (UK)
    18:30
    Hall B
    Session starts at 18:30
    SAT5.1
    Gaps in the effective management of growth disorders
    Tilman Rohrer (Germany)

    19:00
    Hall B
    Session starts at 18:30
    SAT5.2
    Evidence-based eHealth tools

    19:30
    Hall B
    Session starts at 18:30
    SAT5.3
    Understanding non-adherance to design personalised interventions